Cryopreserved allograft veins as alternative coronary artery bypass conduits: Early phase results

Laub, Glenn W.; Muralidharan, S; Clancy, Robert; Eldredge, W. Jay; Chen, Chao; Adkins, Mark S.; Fernández, Javier; Anderson, William A.; McGrath, Lynn B.

doi:10.1016/0003-4975(92)90632-e

Cited by 52 publications

(31 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, when satisfactory autologous SVGs are not available, cryopreserved homologous SVGs, either cryopreserved or denatured, can be an alternative conduit to the autologous ones in coronary artery bypass,127 construction of aortopulmonary communication,77 a modified Blalock-Taussig shunt,7879 and complex limb-salvage procedures 128129. Some authors127130131 have suggested that use of such conduits should be limited due to poor patency. Despite various types of stents that have been used to treat atherosclerotic stenoses of coronary, renal, and superficial femoral arteries, open surgery is still the treatment of choice when the angioplasty fails and the patient develops recurrent symptoms 15.…”

Section: Discussionmentioning

confidence: 99%

A Reappraisal of Saphenous Vein Grafting

Yuan

Hua

2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

Autologous saphenous vein grafting has been broadly used as a bypass conduit, interposition graft, and patch graft in a variety of operations in cardiac, thoracic, neurovascular, general vascular, vascular access, and urology surgeries, since they are superior to prosthetic veins. Modified saphenous vein grafts (SVG), including spiral and cylindrical grafts, and vein cuffs or patches, are employed in vascular revascularization to satisfy the large size of the receipt vessels or to obtain a better patency. A loop SVG helps flap survival in a muscle flap transfer in plastic and reconstructive surgery. For dialysis or transfusion purposes, a straight or loop arteriovenous fistula created in the forearm or the thigh with an SVG has acceptable patency. The saphenous vein has even been used as a stent cover to minimize the potential complications of standard angioplasty technique. However, the use of saphenous vein grafting is now largely diminished in treating cerebrovascular disorders, superior vena cava syndrome, and visceral revascularization due to the introduction of angioplasty and stenting techniques. The SVG remains the preferable biomaterial in coronary artery bypass, coronary ostioplasty, free flap transfer, and surgical treatment of Peyronie disease. Implications associated with saphenous vein grafting in vascular access surgery for the purpose of dialysis and chemotherapy are considerable. Vascular cuffs and patches have been developed as an important and effective means of enhancing the patency rates of the grafts by linking the synthetic material to the receipt vessel. In addition, saphenous veins can be a cell source for tissue engineering. We review the versatile roles that saphenous vein grafting has played as well as its current status in therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A Reappraisal of Saphenous Vein Grafting

Yuan

Hua

2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

show abstract

“…Additionally it should be inexpensive and should promote good pulmonary artery growth, should not produce distortion and should be easy to take down. Encouraged by its use in coronary artery bypass grafting 11,13,14 and peripheral vessel revascularization 15,16 , homograft SVG has been used as a substitute for BTS with variable results [5][6][7][8] . Inspired by these reports we conducted this randomized controlled trial.…”

Section: Discussionmentioning

confidence: 99%

Homograft saphenous vein versus polytetrafluoroethylene graft for modified Blalock -Taussig shunt

Bishnoi¹,

Talwar²,

Choudhary

et al. 2008

Indian J Thorac Cardiovasc Surg

View full text Add to dashboard Cite

“…Eventually, infl ammatory cells will induce the release of growth factors and cytokines, stimulating the repair process and contributing to the proliferation, migration and matrix secretion of smooth muscle cells (SMCs), which leads to the development of intimal hyperplasia and stenosis of the lumen in the homograft (Fellstrom et al , 1999;Simon et al , 2000;Jurado et al , 2002). When used for CABG surgery, cryopreserved SVG homografts have shown unacceptably poor patency rates (Gelbfi sh et al , 1986;Sellke et al , 1991;Laub et al , 1992;Iaffaldano et al , 1995;Bilfi nger et al , 1997). This demonstrates that the complex cellular content of homografts creates an immune response that is above the threshold tolerated by the human body.…”

Section: Homograftsmentioning

confidence: 99%